Table 4 Unpublished phase III trials of immunotherapy for TNBC
From: Recent advances in therapeutic strategies for triple-negative breast cancer
Drugs | Intervention | Register ID | Study population | Status |
|---|---|---|---|---|
Atezolizumab | Atezolizumab to carboplatin and nab-paclitaxel | NCT02620280 | Early high-risk and locally advanced TNBC | Active, not recruiting |
Neoadjuvant chemotherapy with atezolizumab | NCT03281954 | TNBC | Active, not recruiting | |
Atezolizumab plus nab-paclitaxel | NCT04148911 | Inoperable locally advanced or metastatic TNBC | Active, not recruiting | |
Atezolizumab plus chemotherapy | NCT03371017 | Inoperable recurrent TNBC | Recruiting | |
Atezolizumab with adjuvant anthracycline/taxane-based chemotherapy | NCT03498716 | Stage II-III TNBC | Recruiting | |
Atezolizumab with ipatasertib and paclitaxel | NCT04177108 | Inoperable locally advanced or metastatic TNBC | Active, not recruiting | |
Avelumab | Avelumab as adjuvant or postneoadjuvant treatment | NCT02926196 | High-risk TNBC | Active, not recruiting |
Camrelizumab | Camrelizumab plus chemotherapy | NCT04613674 | Early or locally advanced TNBC | Recruiting |
Serplulimab | Serplulimab combined with chemotherapy | NCT04301739 | TNBC | Not yet recruiting |
Toripalimab | Toripalimab combined with nab-paclitaxel | NCT04085276 | Recurrent or metastatic TNBC | Recruiting |
Carelizumab | Carelizumab combined with nab-paclitaxel and apatinib; carelizumab plus nab-paclitaxel; or nab-paclitaxel | NCT04335006 | Inoperable locally advanced or metastatic TNBC | Recruiting |
TQB2450 | TQB2450 combined with anlotinib hydrochloride versus paclitaxel | NCT04405505 | TNBC | Not yet recruiting |
Adagloxad simolenin | Anti-Globo-H vaccine adagloxad simolenin (OBI-822)/OBI-821 | NCT03562637 | Early Globo-H+ TNBC | Recruiting |